PIPE-307 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	2

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,340 /  Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04941781 (ClinicalTrials.gov)	September 1, 2021	18/6/2021	PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy of PIPE-307 in Healthy Volunteers	A Phase 1, Open-label Study of PIPE-307 to Determine Muscarinic Type I Receptor (M1AChR) Occupancy Parameters by [11C] PIPE-307 PET Imaging in Healthy Volunteers	Multiple Sclerosis	Drug: PIPE-307	Pipeline Therapeutics, Inc.	NULL	Completed	25 Years	65 Years	All	6	Phase 1	United Kingdom
2	NCT04725175 (ClinicalTrials.gov)	February 26, 2021	18/1/2021	Phase I Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of of PIPE-307 and Food Effect in Healthy Volunteers	A Phase I, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of PIPE-307 and Food Effect in Normal Healthy Volunteers	Multiple Sclerosis	Drug: PIPE-307;Drug: Placebo oral tablet	Pipeline Therapeutics, Inc.	NULL	Completed	18 Years	55 Years	All	70	Phase 1	Australia